EffRx Obtains Swiss Marketing Authorization for Alkindi® for Paediatric Adrenocortical Insufficiency

FREIENBACH, Switzerland –-BUSINESSWIRE— EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced that Swissmedic has approved Alkindi® for the treatment of paediatric adrenocortical insufficiency (AI). Alkindi®, developed by Diurnal Group plc, is the first preparation of hydrocortisone specifically designed for use in children suffering from paediatric adrenocortical

Learn More

EffRx Obtains Swiss Marketing Authorization for Bronchitol® in Cystic Fibrosis

FREIENBACH, Switzerland –(BUSINESS WIRE)–EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced that Swissmedic has approved Bronchitol® (inhaled mannitol) for the treatment of cystic fibrosis (CF) in adults and in children aged 6 years and above as add‐on to other medicines. Bronchitol® is a precision spray‐dried

Learn More

EffRx Announces the Appointment of Göran Linder to of the Board of Directors

Freienbach, July 21, 2021 — EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the late-stage development and commercialization of prescription medications for niche and orphan indications, today announced the appointment of Göran Linder to its Board of Directors. “As the representative of EffRx’s major shareholder, I actively promoted the turn-around that the company and

Learn More

A Prospective Study in More Than 1,000 Osteoporosis Patients Concluded That Binosto® (Buffered Soluble Alendronate) May Increase Patient Satisfaction, Long-Term Adherence and Therefore Efficacy

FREIENBACH, Switzerland–(BUSINESS WIRE)– Corporate IR Press Release In a newly published international multicenter study1 in over 1,000 osteoporosis patients treated with Binosto® and followed for 12 ± 3 months, Binosto was well tolerated Treatment persistence was high Mean overall compliance was high too Patient satisfaction remained at approximately 90% EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical

Learn More

EffRx Seeks New Business Collaborations at the BIO International Convention Digital 2021

At the BIO International Convention Digital, taking place June 10-11 & 14-18, 2021, EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases. Registered companies can still meet with EffRx in virtual BIO One-On-One Partnering meetings. Please contact us via the partnering platform or at info@effrx.com. BIO is

Learn More

Dr. Nathalie Véron Appointed Director Technical Operations & Qualified Person at EffRx Pharmaceuticals

FREIENBACH, Switzerland – EffRx Pharmaceuticals SA is pleased to announce the appointment of Dr. Nathalie Véron as Director Technical Operations & Qualified Person. She is responsible for overseeing all technical operations activities at EffRx, such as manufacturing relations, supply chain and quality management. Prior to joining EffRx, Dr. Véron has held various local and global,

Learn More

EffRx Pharmaceuticals Announces the Release of Binosto® Data in Two Publications

FREIENBACH, Switzerland – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced the publication of new scientific data on its Binosto® (buffered soluble alendronate). The data appeared in two major medical journals.1,2 The findings from the study “A novel effervescent formulation of oral weekly alendronate (70

Learn More

EffRx Pharmaceuticals Signs Exclusive License Agreement with Dipharma SA and Launches Miglustat Dipharma in Switzerland

FREIENBACH, Switzerland – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Dipharma SA, a Swiss specialty pharmaceutical company, developing high quality, improved medicines for rare diseases. Under the terms of the agreement, EffRx has received

Learn More

EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi® and Submits Market Authorization Application in Switzerland

FREIENBACH, Switzerland (BUSINESS WIRE)-– EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, a specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, for the registration and commercialization of Alkindi® for pediatric adrenocortical

Learn More

World Osteoporosis Day – WOD marked on October 20th: THAT’S OSTEOPOROSIS

Countdown to World Osteoporosis Day: A digital countdown checklist is an easy way to learn good bone health basics. Get Started Now! WOD, marked on October 20 each year, is a year-long campaign dedicated to raising global awareness of the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. It aims to put bone

Learn More

EffRx Pharmaceuticals | EffRx